| Name | Pimodivir |
| Description | Pimodivir (VX-787), an influenza A virus polymerases inhibitor via oral, interacts with the viral PB2 subunit. |
| Cell Research | Pimodivir is dissolved in DMSO.The compound cytotoxicity and efficacy testing is performed in 96-well plates with macrophages at 95% confluence. The compounds are added to the medium, and 30 min later, the cells are infected with virus or non-infected. The cell viability is analyzed with the Cell Titer Glo assay at 24 hpi. The luminescence is read with a PHERAstar FS plate reader. |
| Kinase Assay | Virus sensitivity to neuraminidase inhibitors is determined by the chemiluminescent neuraminidase inhibitor assay using an NA-XTD kit. Viruses are diluted in NA-XTD assay buffer (26 mM morpholineethanesulfonic acid, 4 mM CaCl2 [pH 6.0]) such that the signal-to-noise ratio is greater than 40:1. Resistance is defined as determination of a 50% inhibitory concentration greater than 10-fold the mean for the type/subtype |
| Animal Research | The mice, infected intranasally with influenza virus, are given Pimodivir(prepared in 0.5% methylcellulose) twice a day. |
| In vitro | Pimodivir is very potent against influenza A strains,and shows potent activity against all influenza A virus strains tested, with an EC50 range of 0.13 to 3.2 nM. |
| In vivo | In mouse influenza model,Pimodivir (1, 3, or 10 mg/kg, bid) provided complete survival. Pimodivir (2, 6, and 20 mg/kg/day, p.o.) completely prevent death in the H1N1pdm virus infection in mice. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.01 mM), Sonication is recommended.
DMSO : 60 mg/mL (150.23 mM), Sonication is recommended.
|
| Keywords | VX787 | VX 787 | Pimodivir | Inhibitor | inhibit | InfluenzaVirus | Influenza Virus | Influenza A polymerases |
| Inhibitors Related | Acetylcysteine | α-Vitamin E | AEBSF hydrochloride | Molnupiravir | Nitazoxanide | Camphor | Curcumin | N-Acetylneuraminic acid | Naringenin | Salcomine | Crystal Violet | β-Cyclodextrin |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | ReFRAME Related Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-COVID-19 Compound Library | Anti-Infection Compound Library |
United States
